This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moving Average Crossover Alert: Dynavax (DVAX)
by Zacks Equity Research
Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Dynavax Technologies (DVAX) closed at $3.87, marking a -1.53% move from the previous day.
Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed the most recent trading day at $4.17, moving +0.72% from the previous trading session.
Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed the most recent trading day at $4.22, moving +0.24% from the previous trading session.
Implied Volatility Surging for Dynavax (DVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
Implied Volatility Surging for Dynavax (DVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Dynavax Technologies (DVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -12.50% and -53.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Will Dynavax Technologies (DVAX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
by Zacks Equity Research
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
Dynavax Technologies (DVAX) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed the most recent trading day at $10.12, moving -0.3% from the previous trading session.
Dynavax Signs a Pact to Develop Universal Influenza Vaccine
by Zacks Equity Research
Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Dynavax Technologies (DVAX) closed at $8.51, marking a -1.73% move from the previous day.
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
by Ritujay Ghosh
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVAX) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Dynavax Technologies
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dynavax's Partner Doses First Patient in Coronavirus Study
by Zacks Equity Research
Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.
Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.
Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.